Media

The Motley Fool reports on the exciting news that Race has received today. The US Food and Drug Administration (FDA) has extended Rare Paediatric Disease Designation to RC220 bisantrene for the treatment of paediatric acute myeloid leukemia. Read the full analysis here.

The Australian reports that The US Food and Drug Authority (FDA) has extended Rare Paediatric Disease Designation (RPDD) to Race’s oncology drug RC220 bisantrene for paediatric acute myeloid leukemia (AML). The RPDD in paediatric AML may qualify Race to be eligible for a Priority Review Voucher (PRV). Race’s Executive Director, Dr Peter Smith, explains in…

Proactive reports that Race has hit a new 12-month high on fielding some strong preclinical findings on the efficacy of lead asset bisantrene in treating multiple myeloma. Race CEO Dr Daniel Tillett commented: “The potential for using bisantrene to not only better treat multiple myeloma, but also protect patients from the heart damage caused by carfilzomib,…

The United States Food and Drug Administration (FDA) has extended Orphan Drug Designation (ODD) to our proprietary formulation of bisantrene, RC220, for acute myeloid leukemia. Race CEO Dr Daniel Tillett spoke with Proactive about this significant announcement and the commercial advantage that the ODD will bring to bisantrene. Read the full report here.

Race CEO Dr Daniel Tillett sits down with Juliette Saly at ausbiz for a check-in on the company’s performance in the last quarter, and the outlook for the rest of the year. Dr Tillett says one of the most notable achievements in the quarter was the news that Race’s RC220 bisantrene formulation met all cGMP…

Race CEO Dr Daniel Tillett speaks to Nadine McGrath at Stockhead in detail about drug repurposing and resurrecting abandoned or underutilised drugs. Dr Tillet explains how commercial decisions contribute to whether a drug makes it to market or not. He further lists examples of companies that succeeded in drug repurposing. Read the full article here